DDInter1042 DDInter904
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Idarubicin {u} (Compound) treats {v} (Disease) breast cancer
Idarubicin {u} (Compound) binds {v} (Gene) CYP2C9
Idarubicin {u} (Compound) upregulates {v} (Gene) MEGF8
Idarubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Idarubicin {u} (Compound) downregulates {v} (Gene) CBR3
Idarubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Idarubicin (Compound) resembles Valrubicin (Compound)
Idarubicin (Compound) treats breast cancer (Disease)
Idarubicin (Compound) binds CYP2C9 (Gene)
Idarubicin (Compound) upregulates MEGF8 (Gene)
Idarubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Idarubicin (Compound) downregulates CBR3 (Gene)
Idarubicin (Compound) causes Haemorrhage (Side Effect)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole